James Owens, MD
Psychiatry · Salina, KSNPI 1063492528
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $375,432 of the $432,541 with a category attached, or 86.8%. 15 manufacturers reported payments, led by AbbVie at 34.2% of the total. Among psychiatry clinicians in KS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 444 payments — averaging $974.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$148K
- Otsuka America Pharmaceutical, Inc.$124K
- Alkermes, Inc.$74K
- Johnson & Johnson$45K
- Axsome Therapeutics, Inc.$40K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$405
- plus $729 from 9 others
What the payments were for
- Consulting fees$31,9607%
- Speaking & faculty fees$375,43287%
- Travel & lodging$17,1444%
- Food & beverage$7,8462%
- Education$1590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 121 | $147,976 |
| Otsuka America Pharmaceutical, Inc. | 121 | $124,418 |
| Alkermes, Inc. | 92 | $74,108 |
| Johnson & Johnson | 41 | $45,123 |
| Axsome Therapeutics, Inc. | 37 | $39,782 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $405 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 5 | $239 |
| Supernus Pharmaceuticals, Inc. | 1 | $122 |
| Ironshore Pharmaceuticals Inc. | 3 | $88 |
| Lundbeck LLC | 5 | $85 |
| Neurocrine Biosciences, Inc. | 4 | $66 |
| Sunovion Pharmaceuticals Inc. | 4 | $55 |
| Jazz Pharmaceuticals Inc. | 2 | $36 |
| Vanda Pharmaceuticals Inc. | 1 | $20 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$291,362
- VRAYLAR$146,755
- REXULTI$122,718
- INVEGA SUSTENNA$44,537
- INVEGA TRINZA$44,434
- Auvelity$39,013
- ABILIFY MAINTENA$768
- ARISTADA$417
- SPRAVATO$241
- CAPLYTA$222
- QELBREE$122
- ABILIFY ASIMTUFII$112
- ARISTADA INITIO$104
How this compares
$432,541 in reported general payments places this provider in the 95th percentile of 259 psychiatry providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 26 | $215,906 |
| VraylarCariprazine Hcl | 95 | $137,618 |
| Abilify MaintenaAripiprazole | 48 | $136,319 |
| Invega SustennaPaliperidone Palmitate | 27 | $84,583 |
| AristadaAripiprazole Lauroxil | 22 | $74,484 |
| RexultiBrexpiprazole | 60 | $70,785 |
| LybalviOlanzapine/Samidorphan Malate | 43 | $56,042 |
| CaplytaLumateperone Tosylate | 21 | $30,413 |
| TrintellixVortioxetine Hydrobromide | 55 | $30,233 |
| AbilifyAripiprazole | 16 | $25,178 |
| Lurasidone Hcl | 83 | $17,354 |
| Paliperidone ErPaliperidone | 46 | $14,926 |
| BelsomraSuvorexant | 32 | $13,445 |
| Aripiprazole | 152 | $12,884 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 67 | $10,344 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $66 | $215,90626 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $124,418 | $207,103108 claims |
| AbbVieVraylar | $147,976 | $137,61895 claims |
| Alkermes, Inc.Aristada, Lybalvi | $74,108 | $130,52665 claims |
| Johnson & JohnsonInvega Sustenna, Invega | $45,123 | $94,53149 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $405 | $30,41321 claims |
| E.r. Squibb & Sons, L.L.C.Abilify | $18 | $25,17816 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 259 psychiatry providers in Kansas.
Other psychiatry in Salina
- George JerkovichSalina$4K
- David WichmanManhattan$613K
- Kevin MaysLeawood$548K
- Sheldon PreskornWichita$498K
- Sasha HamdaniOverland Park$104K
- Christine GlennKansas City$58K
- Heidi OgdenWichita$55K
- Mark RomereimHays$41K
- Patrick StangGreat Bend$28K
- Ralph BharatiWichita$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.